A
Amit M. Oza
Researcher at Princess Margaret Cancer Centre
Publications - 542
Citations - 25057
Amit M. Oza is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 65, co-authored 485 publications receiving 19164 citations. Previous affiliations of Amit M. Oza include University Health Network & Ontario Institute for Cancer Research.
Papers
More filters
Journal ArticleDOI
Feasibility of monitoring response to the PARP inhibitor rucaparib with targeted deep sequencing of circulating tumor DNA (ctDNA) in women with high grade ovarian carcinoma on the ARIEL2 trial
A.M. Piskorz,K. Lin,J. Morris,Elaina Mann,Amit M. Oza,Robert L. Coleman,David M. O'Malley,Michael Friedlander,J.M. Cragun,L. Ma,Heidi Giordano,Mitch Raponi,Iain A. McNeish,Elizabeth M. Swisher,James D. Brenton +14 more
Journal ArticleDOI
Moving Beyond BRCA-Incorporating Molecular Assays into Ovarian Cancer Trials.
TL;DR: PrOTYPE is a locked down assay validated to Institute of Medicine standards, using NanoString technology to classify high-grade serous ovarian cancer into four defined subgroups, and its role in influencing treatment decisions is defined.
Proceedings ArticleDOI
Abstract AP28: BRCA1 and RAD51C Promoter Hypermethylation Confer Sensitivity to PARP Inhibitors in Patients with Platinum Sensitive Ovarian Carcinoma
Elizabeth M. Swisher,Maria I. Harrell,Kevin K. Lin,Clare L. Scott,Sandra Goble,Amit M. Oza,Robert L. Coleman,Gottfried E. Konecny,Anna V. Tinker,David M. O'Malley,Rebecca Kristeleit,Ling Ma,James D. Brenton,Katherine M. Bell-McGuinn,Ana Oaknin,Alexandra Leary,Elaina Mann,Heidi Giordano,Mitch Rapon,Iain A. McNeish,Scott H. Kaufmann +20 more
TL;DR: In cases with no BRCA mutations, a high fraction of genomic loss of heterozygosity (LOH) significantly predicted a better progression-free survival, longer duration of response, and a higher fraction of responders compared to cases with low LOH.
Journal ArticleDOI
A multicenter, phase II study of cisplatin, irinotecan and epirubicin (PIE) administered every 3 weeks in patients with unresectable, locally advanced/metastatic cervical carcinoma
TL;DR: Recurrent and metastatic cervical cancer is not curable with conventional therapy, and the median survival is only about 9 months, but high objective response rates have been reported.
Proceedings ArticleDOI
2 Exploratory analysis of postprogression and patient-centered outcomes in ariel3: a phase 3, randomized, placebo-controlled study of rucaparib maintenance treatment in patients with recurrent ovarian carcinoma
Robert L. Coleman,Amit M. Oza,Domenica Lorusso,Carol Aghajanian,Ana Oaknin,Andrew Dean,Nicoletta Colombo,Johanne I Weberpals,Andrew R Clamp,Giovanni Scambia,Alexandra Leary,Robert W. Holloway,M. Amenedo Gancedo,Peter C.C. Fong,Jeffrey C. Goh,David M. O'Malley,Sandra Goble,T. Cameron,Josh Bedel,Jonathan A. Ledermann +19 more
TL;DR: Rucaparib significantly improved clinically meaningful postprogression outcomes vs placebo in the BRCA-mutant cohort and ITT population and the updated safety profile of rucAParib in ARIEL3 was consistent with prior reports.